A new treatment for rare muscular disease
UC researchers present findings that could give patients with Pompe disease a better quality of life
Rare diseases are sometimes the most difficult to treat because of a lack of research and fewer participants to study.
An example would be those who have Pompe disease, a genetic condition when a body can't make a protein that breaks down a complex sugar, called glycogen, for energy. Too much glycogen builds up and damages muscles and organs. The disease causes muscle weakness and trouble breathing and can affect the heart and muscles.
In the case of Pompe disease, however, University of Cincinnati researchers have found a newer, more effective treatment for the rare condition that could become the new standard of care.
Hani Kushlaf, MD, an associate professor in both the Department of Neurology and Rehabilitation Medicine and the Department of Pathology and Laboratory Medicine at UC and principal investigator of a study led at UC, will present findings on this new treatment virtually at the American Academy of Neurology on April 20.
Hani Kushlaf, MD, an associate professor in both the Department of Neurology and Rehabilitation Medicine and the Department of Pathology and Laboratory Medicine at UC and principal investigator of the study. Photo/UC Health
Kushlaf, a UC Health physician, says Pompe disease affects about 1 in 40,000 people in the United States. It can impact children, but it can also present later in life as well. Left untreated, it can result in progressive loss of function of muscles in limbs and respiration leading to the need for wheelchair use and respiratory support.
“In this clinical trial, we tested a new drug, or enzyme replacement therapy (avalglucosidase alfa), to see if it was more effective and safer than the currently approved therapy, also an enzyme replacement therapy, in patients with late-onset Pompe disease,” he says. “It turns out that it is safer and more effective than the current FDA-approved therapy. This new enzyme will likely become the standard of care for patients with the disease and has already been submitted for Food and Drug Administration approval. This is a big deal for patients with this rare disease, as t-PA was for stroke.”
These results are extremely promising for finding a new and effective treatment for [Pompe] disease.
Hani Kushlaf, MD
This study was double-blinded, meaning neither the participants nor the researchers knew which treatment was being administered via an infusion. In 51 patients who received the new treatment, researchers saw an improvement in respiratory muscle function, endurance and muscle strength, in addition to an overall better quality of life, when compared to patients on the current standard of care therapy.
“These results are extremely promising for finding a new and effective treatment for this disease,” adds Kushlaf, who is also a member of the UC Gardner Neuroscience Institute. “With these results, we can take the next steps in having it used widely in this patient population, improving their outcomes and giving them a better life.”
Featured photo of lungs by iStock.
Impact Lives Here
The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.
Stay up to date on all UC's COVID-19 stories, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.
The trial is sponsored by the pharmaceutical company Sanofi. Kushlaf belongs to an author group appointed by Sanofi and is responsible for disseminating the findings of this trial.
Related Stories
We love ‘Lucy’ — the AI avatar redefining UC tech transfer
July 17, 2024
In a visionary leap at the University of Cincinnati, the marriage of artificial intelligence and interactive technology has birthed "Lucy," a Smarthelp AI avatar poised to revolutionize how regional industries engage with UC's tech transfer initiatives.
NIS program opens new horizons for international student
July 17, 2024
In his pursuit of physics and a taste for research, Akash Khanikor ventured from his hometown in India's Assam to the University of Cincinnati, drawn by the promise of hands-on exploration early in his undergraduate career as a NEXT Innovation Scholar.
Camp aims to empower children, teens who stutter
July 17, 2024
A one-week, evidence-based program for children and teens who stutter at the University of Cincinnati will teach kids to communicate effectively, advocate for themselves and develop confidence about their communication abilities. Camp Dream. Speak. Live., which is coming to Cincinnati for the first time July 22-26, began in 2014 at the University of Texas at Austin. The Arthur M. Blank Center for Stuttering Education and Research at UT expects to serve more than 2,000 children at camps across the United States, Africa, Asia and Europe this year.